The data presented here suggest that dasatinib may be an effective agent for reducing the secretion of IFN-γ and TNF-α by activated CAR123, thereby reducing CD123 upregulation on endothelial cells and minimizing the on-target/off-tumor effect of CAR123. Here, TNF is linked to neoplasm.